AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26787687
Drug: Surotomycin 500
RxNorm normalized name: Surotomycin
DrugBank: Surotomycin (DB12076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surotomycin 500 mg twice daily for 14 days
Trial: 26787687
Drug: Surotomycin 1000
RxNorm normalized name: streptomycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surotomycin 1000 mg twice daily for 14 days
Trial: 25176098
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.5 mg bevacizumab
Trial: 25176098
Drug: Non-intravitreal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intravitreal treatment (only vitreous operation and membrane peeling)
Trial: 18674471
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d atorvastatin
Trial: 22135385
Drug: 20-40 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-40 mg/d simvastatin
Trial: 20560292
Drug: Pentoxifylline (1200-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200-2000 mg/day)
Trial: 10447227
Drug: Clodronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (400 mg capsules twice a day for 2 years)
Trial: 24988203
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no additional therapy)
Trial: 7499633
Drug: Questionnaire administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Questionnaire administered before physician or family nurse practitioner visit
Trial: 1948517
Drug: Ceftizoxime 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime 250 mg IM
Trial: 2264006
Drug: Ceftizoxime 500
RxNorm normalized name: ceftizoxime 500 mg injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime 500 mg IM
Trial: 30764648
Drug: CBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT plus medication (escitalopram)
Trial: 30764648
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus CBT (CBT added after antidepressant)
Trial: 30764648
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (CBT plus medication or medication plus CBT)
Trial: 30764648
Drug: CBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT plus medication and Medication plus CBT
Trial: 25993594
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg/day) plus standard ADHF therapy
Trial: 25993594
Drug: Standard ADHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ADHF therapy alone (Control)
Trial: 22146614
Drug: Alfentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 20 μg kg(‐1)
Trial: 17985810
Drug: 270 mg
RxNorm normalized name: leucine 270 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mg citrus flavonoids plus 30 mg tocotrienols (S)
Trial: 15848148
Drug: Perception of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perception of oral dryness ratings using Visual Analog Scales.
Trial: 15848148
Drug: Perception of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perception of oral wetness in low and very low UWSFR groups at 11:30 a.m.
Trial: 14511846
Drug: Lercanidipine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 5 mg
Trial: 9869018
Drug: Lercanidipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 2.5 mg
Trial: 9869018
Drug: Lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 10 mg (24 h ambulatory)
Trial: 9869018
Drug: Lercanidipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 2.5 mg (24 h ambulatory)
Trial: 9869018
Drug: Lercanidipine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 5 mg (24 h ambulatory)
Trial: 9869018
Drug: Smoothness index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoothness index for 2.5 mg lercanidipine
Trial: 9869018
Drug: Smoothness index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoothness index for 5 mg lercanidipine
Trial: 9869018
Drug: Smoothness index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoothness index for 10 mg lercanidipine
Trial: 2223155
Drug: Bestatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin treatment in invasive treatment group
Trial: 2223155
Drug: Bestatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin treatment in non-invasive treatment group
Trial: 2223155
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group in invasive treatment
Trial: 2223155
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group in non-invasive treatment
Trial: 31919773
Drug: Aflibercept monotherapy
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept monotherapy (group B)
Trial: 26348542
Drug: Camicinal (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal (125 mg)
Trial: 23464844
Drug: Ciprofloxacin-resistant Gram-negative
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin-resistant Gram-negative coliforms identified in rectal flora
Trial: 21183734
Drug: INV-403 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INV-403 (20 mg/kg per day)
Trial: 11020741
Drug: CP‐122,721 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐122,721 200 mg
Trial: 11020741
Drug: CP‐122,721 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐122,721 100 mg
Trial: 11020741
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CP‐122,721 200 mg + ondansetron 4 mg)
Trial: 1739372
Drug: MDC (multiple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDC (multiple-dose charcoal)
Trial: 6386031
Drug: Superficial X-ray
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial X-ray therapy (100 rad at 50 kV on three occasions at intervals of 21 days)
Trial: 6386031
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (control hand)
Trial: 23609584
Drug: Dry needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling therapy
Trial: 28158152
Drug: Cross tape
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross tape therapy
Trial: 25187003
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation (CS) - 10 twice weekly meetings focused on a specific cognitive area.
Trial: 24083759
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant EGF-based cream
Trial: 18304284
Drug: Transdermal E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2/NETA (50 microg/140 microg)
Trial: 16444068
Drug: Gonadotrophin releasing
RxNorm normalized name: Gonadotrophin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin releasing hormone agonists (GnRH agonists)
Trial: 15041351
Drug: CsA microemulsification
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA microemulsification formulation (CsA‐ME)
Trial: 8507027
Drug: 0.05% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% NaF rinse used once daily
Trial: 8507027
Drug: 0.4% SnF2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% SnF2 gel applied twice daily
Trial: 8507027
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between 0.05% NaF rinse and 0.4% SnF2 gel
Trial: 25335123
Drug: High-dose Epoetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Epoetin beta (30,000 IU on days 1, 2, and 3)
Trial: 25335123
Drug: Low-dose Epoetin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11, and 13)
Trial: 23532835
Drug: Existential behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existential behavioural therapy (EBT)
Trial: 20006168
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin (300 microg)
Trial: 20006168
Drug: Blood transfusion
RxNorm normalized name: Blood transfusion, auxiliary products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood transfusion (fresh frozen plasma 10 mL/kg and/or 1 unit of single donor platelets)
Trial: 16632019
Drug: Oral fludrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fludrocortisone (0.1 mg/d; n = 18)
Trial: 16632019
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control; n = 19)
Trial: 12955758
Drug: Static magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Static magnetic field (SMF) combined with antineoplastic chemotherapy
Trial: 10998482
Drug: LDL-apheresis (LA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-apheresis (LA) with concomitant simvastatin administration
Trial: 30153382
Drug: Levothyroxine sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine sodium oral solution (4 × 150-μg unit-dose ampules) with water
Trial: 30153382
Drug: Levothyroxine sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine sodium oral solution (4 × 150-μg unit-dose ampules) without water
Trial: 30153382
Drug: Levothyroxine sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine sodium soft capsule (4 × 150-μg capsules) with water
Trial: 25265768
Drug: Neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.5 mg, glycopyrrolate 0.2 mg and atropine 0.6 mg
Trial: 22459700
Drug: Active radiation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active radiation treatment (890-nm wavelength, 6 sessions of 40 minutes each)
Trial: 22459700
Drug: Placebo radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo radiation treatment
Trial: 22459700
Drug: Active radiation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active radiation treatment (890-nm wavelength)
Trial: 20064223
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) implemented in 11 health sub-districts.
Trial: 9118819
Drug: Dexfenfluramine 15mg
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine 15mg twice daily with dietary support
Trial: 1396480
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran concentrate (11.2 g of beta-glucan daily)
Trial: 21248153
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug users (IDUs)
Trial: 18314197
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug users (IDUs) without endocarditis
Trial: 12633131
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (STS), 20 mg/20 cm², daily for up to 8 weeks
Trial: 11862376
Drug: Cortisol (hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (hydrocortisone 20 mg)
Trial: 10207191
Drug: Carisolv method
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisolv method (gel treatment)
Trial: 2189417
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of ciamexon
Trial: 2189417
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of ciamexon
Trial: 219802
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (large doses of oral conjugated estrogen for three months)
Trial: 219802
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered for a comparable period)
Trial: 6341417
Drug: Timolol-Hydrochlorothiazide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol-Hydrochlorothiazide combination
Trial: 22723573
Drug: Teriflunomide 7
RxNorm normalized name: teriflunomide 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide 7 mg once daily
Trial: 10918432
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron
Trial: 8849763
Drug: One enema,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One enema, self administered at home two hours before the test
Trial: 8849763
Drug: Two enemas,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two enemas, administered the night before and two hours before the test
Trial: 1378141
Drug: Nifedipine sustained-release
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine sustained-release 20 mg twice daily
Trial: 1378141
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of carvedilol and nifedipine SR
Trial: 1378141
Drug: Monotherapy (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (either carvedilol or nifedipine SR)
Trial: 30030308
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no pharmacist-led medication review)
Trial: 26838248
Drug: Mouth-rinse with
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth-rinse with G-CSF (150-300ug plus 100ml-500ml normal saline) for at least 7 days
Trial: 26838248
Drug: Mouth-rinse with
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth-rinse with G-CSF
Trial: 22532515
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg intravenous once yearly
Trial: 9893190
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol dry powder 1600 microg
Trial: 9893190
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol dry powder after placebo pretreatment
Trial: 1675877
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (n = 9)
Trial: 27130812
Drug: Caregivers who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caregivers who perceived it easy to remember medication names
Trial: 27130812
Drug: Caregivers who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caregivers who did not easily remember medication names
Trial: 20562295
Drug: 10 mM
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mM L-NAME
Trial: 20562295
Drug: Combined 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 4 mM theophylline + 10 mM L-NAME
Trial: 20562295
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer solution (control)
Trial: 18589032
Drug: Higher dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher dietary protein intake (0.62 g/kg body weight/day)
Trial: 16025960
Drug: Drug-therapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-therapy plus acupuncture (Group B)
Trial: 16025960
Drug: Drug-therapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-therapy plus ETSM and acupuncture (Group C)
Trial: 16025960
Drug: Drug-therapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-therapy only (Group A)
Trial: 10099859
Drug: Ambulatory withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory withdrawal therapy
Trial: 10099859
Drug: Stationary withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stationary withdrawal therapy
Trial: 8911442
Drug: 4 annual
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 annual doses of ivermectin
Trial: 8911442
Drug: 10 6‐monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 6‐monthly doses of ivermectin
Trial: 6137895
Drug: Opiate analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate analgesics (omnopon, pethidine, pentazocine)
Trial: 6312664
Drug: Naloxone (opiate/opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (opiate/opioid antagonist)
Trial: 20740477
Drug: HandTutor™ combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HandTutor™ combined with traditional therapy
Trial: 15136304
Drug: Enoxaparin sodium
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enoxaparin sodium (low-molecular-weight heparin)
Trial: 11517856
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg/three times a day for 15 days)
Trial: 7560252
Drug: Iloperidone 3
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone 3 mg
Trial: 7560252
Drug: Iloperidone 5
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone 5 mg
Trial: 837172
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g or 200 g of liquorice daily for one to four weeks
Trial: 30777001
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg modafinil taken daily for 6 weeks
Trial: 23444345
Drug: Craniospinal radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Craniospinal radiotherapy (23.4 Gy) plus adjuvant chemotherapy
Trial: 22064991
Drug: Nicotine 2
RxNorm normalized name: nicotine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 2 mg
Trial: 22064991
Drug: Nicotine 4
RxNorm normalized name: nicotine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 4 mg
Trial: 22064991
Drug: Nicotine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (2 mg and 4 mg)
Trial: 10668837
Drug: Nonusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers of antihypertensive drugs
Trial: 7490809
Drug: Anticholinergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic therapy for detrusor instability
Trial: 1593852
Drug: Triple treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple treatment (low-dose cyclosporine, azathioprine, methylprednisolone)
Trial: 1593852
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of two immunosuppressive drugs
Trial: 30795785
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day crocin (2 plus crocin tablet, 15 mg BID)
Trial: 30795785
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets per day, 15 mg BID)
Trial: 19856040
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg isobaric mepivacaine 1.5% plus 10 microg fentanyl (M + F group)
Trial: 19856040
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg isobaric mepivacaine 1.5% (M group)
Trial: 17643363
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate calcium (LCD) 1.25 mmol/l
Trial: 17643363
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium dialysate (HCD) 1.75 mmol/l